Form 4: Director Nilda Mesa's Equity Changes at UTHR

United Therapeutics Director Nilda Mesa reported the vesting of restricted stock units and new equity awards, including stock options and additional restricted stock units.

Summary

• Director Nilda Mesa reported changes in her beneficial ownership of United Therapeutics Corporation (UTHR) equity.
• On July 25, 2025, 590 restricted stock units (RSUs) vested and converted into 590 shares of common stock.
• Following this conversion, Mesa directly owns 5,473 shares of common stock.
• On July 24, 2025, Mesa received an annual non-employee director award consisting of 650 restricted stock units and 1,830 stock options.
• Each restricted stock unit represents the right to receive one share of common stock upon vesting.
• The stock options have an exercise price of $306.41 and expire on July 24, 2035.
• Mesa now directly holds 650 restricted stock units and 1,830 stock options.

Sentiment

Score: 7

Explanation: The filing indicates a director's increased equity stake through new awards and RSU vesting, which generally signals confidence in the company's future and aligns management interests with shareholders.

Positives

• Director Nilda Mesa received new equity awards, including 650 restricted stock units and 1,830 stock options, as part of her annual non-employee director compensation.
• The vesting of 590 restricted stock units into common stock increases the director's direct share ownership, further aligning her interests with shareholders.

Negatives

• None identified.

Risks

• No specific risks related to the company's operations or financial health were disclosed in this filing.

Future Outlook

This filing, a Form 4, does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• No direct management comments or notable quotes were included in this Form 4 filing.

Industry Context

This Form 4 filing details insider equity transactions and does not provide information related to broader industry trends or competitive analysis.

Comparison to Industry Standards

• Not applicable as this filing pertains to individual insider equity transactions rather than company performance metrics.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters were disclosed in this filing.

Related Party Transactions

• The equity awards to Director Nilda Mesa are part of her compensation package and are standard for non-employee directors, not indicative of unusual related-party transactions.

Stakeholder Impact

• Shareholders may view the director's increased equity ownership positively, as it further aligns her interests with those of the company's long-term performance.

Next Steps

• Future vesting of the 650 restricted stock units on or around July 9, 2026.
• Potential exercise of the 1,830 stock options prior to their expiration on July 24, 2035.

Key Dates

Keywords

UTHR, United Therapeutics, Nilda Mesa, Form 4, insider transaction, stock options, restricted stock units, equity awards, director compensation